Challenges of CAR- and TCR-T cell–based therapy for chronic infections

While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections?

Detalles Bibliográficos
Autores principales: Bertoletti, Antonio, Tan, Anthony Tanoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201928/
https://www.ncbi.nlm.nih.gov/pubmed/32163104
http://dx.doi.org/10.1084/jem.20191663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201928/
https://www.ncbi.nlm.nih.gov/pubmed/32163104
http://dx.doi.org/10.1084/jem.20191663

Ejemplares similares